- Home
- VNDA vs TSHA Comparison
VNDA vs TSHA Comparison
Compare VNDA & TSHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VNDA
- TSHA
- Stock Information
- Founded
- VNDA 2002
- TSHA 2019
- Country
- VNDA United States
- TSHA United States
- Employees
- VNDA N/A
- TSHA N/A
- Industry
- VNDA Biotechnology: Pharmaceutical Preparations
- TSHA Biotechnology: Pharmaceutical Preparations
- Sector
- VNDA Health Care
- TSHA Health Care
- Exchange
- VNDA Nasdaq
- TSHA Nasdaq
- Market Cap
- VNDA 237.9M
- TSHA 262.4M
- IPO Year
- VNDA 2006
- TSHA 2020
- Fundamental
- Price
- VNDA $4.33
- TSHA $1.24
- Analyst Decision
- VNDA Strong Buy
- TSHA Strong Buy
- Analyst Count
- VNDA 2
- TSHA 8
- Target Price
- VNDA $16.50
- TSHA $6.63
- AVG Volume (30 Days)
- VNDA 754.6K
- TSHA 2.4M
- Earning Date
- VNDA 05-07-2025
- TSHA 05-13-2025
- Dividend Yield
- VNDA N/A
- TSHA N/A
- EPS Growth
- VNDA N/A
- TSHA N/A
- EPS
- VNDA N/A
- TSHA N/A
- Revenue
- VNDA $198,772,000.00
- TSHA $8,333,000.00
- Revenue This Year
- VNDA $14.36
- TSHA N/A
- Revenue Next Year
- VNDA $44.53
- TSHA N/A
- P/E Ratio
- VNDA N/A
- TSHA N/A
- Revenue Growth
- VNDA 3.18
- TSHA N/A
- 52 Week Low
- VNDA $3.85
- TSHA $1.05
- 52 Week High
- VNDA $6.75
- TSHA $4.32
- Technical
- Relative Strength Index (RSI)
- VNDA 43.42
- TSHA 40.35
- Support Level
- VNDA $4.27
- TSHA $1.05
- Resistance Level
- VNDA $4.46
- TSHA $1.36
- Average True Range (ATR)
- VNDA 0.22
- TSHA 0.17
- MACD
- VNDA 0.01
- TSHA -0.01
- Stochastic Oscillator
- VNDA 54.55
- TSHA 25.68
About VNDA Vanda Pharmaceuticals Inc.
Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products; HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS); Fanapt for the treatment of schizophrenia; and PONVORY. Its other products include VHX-896, ASO Molecules, VQW-765, Tradipitant, VTR-297 and VHX-896. The majority of revenue is derived from the Fanapt product sales. Geographically, the company sells its product predominantly in the United States, and also in Israel, Europe, and Canada.
About TSHA Taysha Gene Therapies Inc.
Taysha Gene Therapies Inc is a patient-centric gene therapy company to eradicate monogenic CNS disease. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the CNS in both rare and large patient populations. The company develops and commercializes transformative gene therapy treatments. Its product pipeline includes, TSHA-102 which is a is a self-complementary intrathecally delivered AAV9 gene transfer therapy in clinical evaluation for Rett syndrome.